Literature DB >> 12377956

Vaccinating patients with autologous tumor.

Paul B Chapman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12377956     DOI： 10.1200/JCO.2002.20.20.4139

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  1 in total

1.  Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Authors:  Ben C Creelan; Scott Antonia; David Noyes; Terri B Hunter; George R Simon; Gerold Bepler; Charles C Williams; Tawee Tanvetyanon; Eric B Haura; Michael J Schell; Alberto Chiappori
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.